Lightlake Therapeutics Inc. Set to Begin Phase II Clinical Trials of Binge Eating Disorder Treatment
Alcoholism Methadone: Lightlake Therapeutics Inc. Set to Begin Phase II Clinical Trials of Binge Eating Disorder Treatment
LONDON–(BUSINESSWIRE)– Lightlake Therapeutics Inc. (OTCBB: LLTP) (“Lightlake” or “the “Company”), an early stage biopharmaceutical company currently developing a nasal spray for the treatment of overweight …
Alcoholism Methadone – Yahoo! News Search Results
Alcoholism Methadone: Press Release
Lightlake Therapeutics Inc. Posted on:24 Aug 11 Dr. Roger Crystal, CEO of Lightlake commented, “We are excited to commence the definitive stage of testing of a product that we believe will be a solution to a disease thought to affect a significant proportion of obese and overweight patients today.
Alcoholism Methadone – Yahoo! News Search Results
Find More Alcoholism Methadone Information…